Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Aiforia raised 4.2 MEUR in a directed share issue

Aiforia Technologies

Summary

  • Aiforia raised approximately 4.2 MEUR through a directed share issue to support its growth strategy, increasing its number of shares by 6.3%.
  • The share issue was conducted at a subscription price of EUR 2.106 per share, representing a typical 10% discount to the pre-issue closing price of EUR 2.34.
  • The offering was smaller and occurred earlier than anticipated, slightly impacting forecasts, but it extends Aiforia's cash sufficiency to the last quarter of 2026.
  • The share issue was expected and necessary, with minor negative effects on valuation, reducing short-term financing risks.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 12/11/2025 at 8:31 am EET.

Aiforia announced on Wednesday evening that it had successfully completed a directed share issue, through which the company raised gross proceeds of around 4.2 MEUR to support the financing of its growth strategy. The share issue was carried out in an accelerated bookbuilding process, and as a result, the number of shares in the company will increase by 6.3%. The issue was expected, although it took place slightly earlier than we predicted, was smaller, and at a slightly lower valuation. The share issue has a minor impact on our forecasts, and we will update our estimates to reflect the increased number of shares and strengthened cash position no later than in connection with the H2 report.

The directed share issue was expected and necessary for financing the company's growth strategy

Aiforia issued 2 million new shares in the offering at a subscription price of EUR 2.106 per share. The share issue increases the company's number of shares by 6.3%, and its pricing corresponded to a typical 10% discount to the closing price (EUR 2.34) before the issue. The share issue came as no surprise to us, as we had already predicted that Aiforia would need additional funding to implement its growth strategy. Aiforia has also recently implemented cost savings to limit its funding needs.

Before the share issue, we estimated that the company's cash would be sufficient until approximately Q2/2026, and we assumed the company would raise a total of 20 MEUR in new equity in 2026 and 2027. The now completed 4.2 MEUR offering is smaller than our estimated 10 MEUR one-off item and was realized earlier than our forecast. With the support of the completed share issue, Aiforia's cash is estimated to be sufficient until around the last quarter of 2026.

Our estimates included share issues at a price of EUR 2.36 per share (the share price level of the previous report published on November 18, 2025, minus 10%), in relation to which the issue was carried out at a price some 11% lower. The share issue thus has only slightly negative effects on our valuation in this respect, and its realization at the same time slightly reduces the company's short-term financing risks. We will incorporate the initially mild effects of the share issue into our forecasts no later than in connection with the company's financial statement release.

 

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more on company page

Key Estimate Figures19.11.2025

202425e26e
Revenue2.93.35.1
growth-%18.9 %16.4 %55.0 %
EBIT (adj.)-12.2-10.9-8.6
EBIT-% (adj.)-427.8 %-328.4 %-167.6 %
EPS (adj.)-0.41-0.39-0.28
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

Clinical revenue plotted here, this is presumably the value driver. By the way, an integration of Aiforia into a US firm’s pathology platform...
20 minutes ago
by Puutaheinää
2
Aiforia Aiforia - Tiedotteet Aiforia on lääketieteen ohjelmistoyritys, joka tarjoaa patologeille ja tutkijoille kliinisissä, prekliinisissä ...
3 hours ago
18
That comes pretty directly from what the company communicates in its targets: was it 50 hospitals by 2030 at a potential of €500,000 each, so...
4 hours ago
by Puutaheinää
7
What does the hive mind think about what the CEO said in the webcast: ”Currently, this list generates a bit over 2 million in recurring revenue...
11 hours ago
by Jekkku
6
Personally, I found the financial statement encouraging and raised my own target prices. The reason was that the scaling of the clinical business...
23 hours ago
by Puutaheinää
17
These target prices really show how difficult it is to set a target price for an early-stage growth company that is still loss-making. I’m referring...
23 hours ago
by JusaVaan
12
Nuways’ interim report update, target remains at €3.8 & Buy. Detailed reasoning behind the link. We make minor adjustments to our model. Given...
yesterday
by Opa
11
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.